Form 4: Alumis Inc. Executive Jorn Drappa Acquires Stock Options

Chief Medical Officer of Alumis Inc., Jorn Drappa, reports acquisition of stock options.

Summary

• Jorn Drappa, Chief Medical Officer of Alumis Inc., filed a Form 4 on February 20, 2025, reporting a transaction on February 18, 2025.
• Drappa acquired stock options for 180,000 shares of Alumis Inc. common stock at an exercise price of $5.06 per share.
• These options vest over time, with 25% vesting on February 18, 2026, and the remainder vesting in equal monthly installments over the subsequent 36 months, contingent upon continuous service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself is a positive sign of incentivization, but the filing is routine.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the executive, aligning their interests with the company's performance over the next several years.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Vesting schedules, like the one described, are standard practice to ensure long-term commitment from executives.
• The specific number of options and exercise price would need to be compared to similar companies and executive roles to determine if they are in line with industry norms.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Form 4, Stock Options, Beneficial Ownership, Alumis Inc., ALMS, Jorn Drappa, Chief Medical Officer